Diazepam: Nursing Drug Guide, Respiratory Depression & NCLEX Review

Diazepam is a Schedule IV benzodiazepine supplied as oral tablets (commonly 2 mg, 5 mg, and 10 mg per labeling), IV injection, and rectal gel (e.g., Diastat) in some settings. Verify strength, route, and indication (anxiety, alcohol withdrawal, muscle spasm, adjunct seizures) on every pass—dose ranges differ by use.

Common U.S. brand example: Valium tablets. Generic diazepam is widely dispensed. Do not interchange with other benzodiazepines (lorazepam, clonazepam) without prescriber and pharmacy verification—potency and half-life differ.

Diazepam is indicated for management of anxiety disorders or short-term relief of anxiety symptoms (everyday stress alone usually does not require an anxiolytic per labeling), symptomatic relief in acute alcohol withdrawal, adjunct relief of skeletal muscle spasm, and as an oral adjunct in convulsive disorders (not proved useful as sole therapy). Use the lowest effective dose for the shortest duration and reassess usefulness when used beyond four months per labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Diazepam is a 1,4 benzodiazepine that enhances the activity of GABA at GABA_A receptors. Clinical effects include anxiolysis, sedation, skeletal muscle relaxation, and anticonvulsant activity when used as an adjunct. After oral dosing, initial distribution half-life is about 1 hour (up to >3 hours in some patients); terminal elimination half-life of diazepam may be up to 48 hours, with active metabolite N-desmethyldiazepam up to 100 hours—sedation and respiratory effects can persist and accumulate across shifts, especially in older adults and hepatic impairment. Because it depresses central respiratory drive—especially with opioids or alcohol—nurses must treat sedation and respiratory rate as primary safety endpoints.

Dosing depends on indication, age, hepatic function, and interacting drugs. Verify each order against current prescribing information and the patient’s opioid and CNS depressant exposure before administration.

Pediatrics: Not for use under 6 months per label. Children: initiate with lowest dose (1–2.5 mg 3–4 times daily) and increase gradually as required and tolerated.

Renal impairment: Not specified in the reviewed prescribing information for dedicated renal dose adjustment; metabolites are substantially excreted by the kidney—use caution and monitor per prescriber/pharmacy in impaired renal function.

Hepatic impairment: Contraindicated in severe hepatic insufficiency; half-life markedly prolonged in cirrhosis and hepatitis—smallest effective dose and close monitoring if used per specialist plan.

Missed dose: If oversedated or new opioids are started, hold and clarify. For patients on continued benzodiazepine therapy, contact prescriber/pharmacy before abrupt gaps—do not double doses.

Pretreatment checks

• Screen the MAR and home med list for opioids, alcohol, sedating antihistamines, and other benzodiazepines—perform medication reconciliation on admission and after every transfer
• Assess respiratory rate, oxygenation (pulse oximetry per protocol), sedation level, and mental status; review history of COPD, severe pulmonary disease, or sleep apnea
• Confirm allergy to diazepam or other benzodiazepines; verify tablet strength, route, indication, and whether a taper is in place if therapy is being reduced
• Screen for myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, and acute narrow-angle glaucoma—contraindications per labeling

Contraindications

• Known hypersensitivity to diazepam
• Pediatric patients under 6 months (insufficient clinical experience per label)
• Myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome
• Acute narrow-angle glaucoma (may be used in open-angle glaucoma on appropriate therapy per label)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablets (2 mg, 5 mg, 10 mg per labeling) swallowed with water; IV and rectal formulations exist in some settings—follow product-specific administration and compatibility checks for IV.

• Controlled substance (Schedule IV): follow institutional controlled-drug counting, wasting, and secure storage requirements
• Individualize dose for maximum benefit; increase cautiously when higher doses are required per label
• When combined with opioids or other CNS depressants, expect additive sedation—stagger assessments and avoid duplicate sedating PRNs
• Changes in salivation (dry mouth or hypersalivation) may occur—consider aspiration risk in patients who cannot handle secretions per label

• Reduced anxiety, tremor, or agitation when used for labeled indications—assess with patient report and observation, not sedation alone
• In alcohol withdrawal, decreasing tremor and agitation without excessive somnolence or inability to arouse
• Stable respiratory rate and oxygenation; perform neurological assessment and Glasgow Coma Scale when sedation or mental status changes
• When used as seizure adjunct, monitor seizure frequency—abrupt withdrawal may temporarily increase seizures per label

Respiratory depression with benzodiazepines—especially plus opioids or alcohol—can progress to coma and death. Diazepam may cause respiratory depression in COPD or sleep apnea. Abrupt discontinuation can precipitate withdrawal seizures. Escalate immediately.

• Respiratory rate below facility threshold, shallow breathing, apnea, or new difficulty breathing—hold diazepam, support airway per protocol, rapid response
• SpO₂ drop, cyanosis, or inability to arouse the patient—treat as respiratory emergency; consider opioid co-ingestion
• Excessive sedation, ataxia, or confusion after a dose or dose increase
• Paradoxical agitation, aggression, hallucinations, or psychosis—discontinue gradually per label; more likely in children and older adults
• Breakthrough seizures, tremor, delirium tremens recurrence, or autonomic instability after missed doses, abrupt stop, or flumazenil—urgent prescriber and neurology input
• Neonatal sedation or withdrawal signs if used late in pregnancy—escalate per maternal–child protocol

↔On a small screen, swipe or scroll sideways to see the full table.

Benzodiazepine overdosage ranges from drowsiness to coma. Severe cases may include respiratory depression. Combined overdose with opioids, alcohol, or other CNS depressants may be fatal. Markedly abnormal vital signs suggest polysubstance involvement.

Early signs

• Somnolence, confusion, dysarthria, ataxia, hypotonia, diminished reflexes
• Paradoxical agitation, irritability, or talkativeness (less common)
• Progressive respiratory depression and coma—especially with co-ingested opioids

Antidote and supportive care

Flumazenil is the specific benzodiazepine receptor antagonist indicated for complete or partial reversal of benzodiazepine sedation in overdosage management. It is an adjunct to airway management—not a substitute. Flumazenil may precipitate withdrawal and seizures, especially with chronic benzodiazepine use, mixed overdoses, or underlying seizure disorders; it is contraindicated when benzodiazepines were given for a potentially life-threatening condition (e.g., status epilepticus).

If opioids are co-involved, naloxone may reverse opioid-mediated respiratory depression per protocol—benzodiazepine effects may persist. Employ supportive measures including IV fluids and airway management per escalation pathways.

• Diazepam vs diltiazem—sound-alike risk in verbal orders; independent double-check name and indication
• Diazepam vs lorazepam vs alprazolam—all are benzodiazepines but differ in half-life, potency, and taper plans; verify MAR name and strength
• Valium strength mix-ups—2 mg, 5 mg, and 10 mg tablets; color may differ by manufacturer—independent double-check
• Oral tablet vs IV vs rectal gel—route and concentration errors are high-risk; verify formulation on MAR
• Duplicate benzodiazepine therapy—home Valium plus ordered lorazepam PRN is a common sedation stack
• Opioid + benzodiazepine orders—apply high-alert medication administration habits; document respiratory monitoring plan

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, depth, and SpO₂—especially when opioids or alcohol are present or pulmonary disease is documented
• Sedation level (e.g., Pasero scale or facility tool), ability to arouse, and blood pressure for hypotension
• Mental status and anxiety/panic symptom response—sedation is not a proxy for therapeutic benefit
• Withdrawal signs if doses are delayed, reduced, or held: tremor, tachycardia, rebound anxiety, insomnia, seizures, delirium tremens recurrence in alcohol withdrawal

Document

• Dose, route, time, indication, and patient response including respiratory status before and after
• Co-administered opioids or CNS depressants on the same shift; any hold and prescriber/pharmacist notification
• Controlled-drug count alignment; taper plan and patient education on why abrupt stops are dangerous

• Do not combine with alcohol, opioid pain medicines, or other sedating drugs unless your prescriber explicitly directs you—and report increased sleepiness immediately
• Do not drive or operate machinery until you know how diazepam affects you, especially when starting or increasing dose or when taking opioids
• Never stop suddenly after regular use—withdrawal can be life-threatening (seizures, delirium tremens); ask for a taper plan
• Keep medication secure (controlled substance); do not share tablets
• Seek urgent care for severe sleepiness, slow or troubled breathing, or inability to stay awake—and contact local poison control or toxicology services per your facility’s overdose guidance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for diazepam with a tabbed case (MAR, vitals, history, nursing notes), then priority action, cue recognition (SATA), respiratory trend interpretation, matrix urgency sorting, alcohol-withdrawal taper judgment, and overdose reversal cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.